17β-Hydroxysteroid dehydrogenase inhibitors: A patent review

Expert Opinion on Therapeutic Patents

Volumn 20, Issue 9, 2010, Pages 1123-1145

  Poirier, Donald ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

17 hydroxysteroid dehydrogenase; Androgen; Cancer; Enzyme; Estrogen; Inhibitor; Steroid; Structureactivity relationship; Therapy

Indexed keywords

1 TETRALONE DERIVATIVE; 16 METHYLENE E2; 2,5 DISUBSTITUTED OXAZOLE; 3 BENZOFURANONE DERIVATIVE; 6 METHYL 2 PYRIDYL DERIVATIVE; BENZOPYRANONE DERIVATIVE; EM 101; EM 150; HYDROXYPHENYL NAPHTHOL; STEROID HORMONE ANTAGONIST; STX 2171; STX 2624; TESTOSTERONE 17BETA DEHYDROGENASE; TETRALIN DERIVATIVE; THIOPHENEPYRIMIDINONE; TRIFLUOROMETHYL ANALOG; UNCLASSIFIED DRUG; 17 OXOSTEROID; ENZYME INHIBITOR; HYDROXYSTEROID DEHYDROGENASE;

CLINICAL STUDY; DRUG MECHANISM; DRUG POTENCY; HORMONAL THERAPY; HORMONE SYNTHESIS; HUMAN; IC 50; NONHUMAN; PROTEIN FUNCTION; REVIEW; STEROIDOGENESIS; STRUCTURE ACTIVITY RELATION; ACNE VULGARIS; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; DRUG DESIGN; ENZYMOLOGY; METABOLISM; NEOPLASM; OSTEOPOROSIS; PATENT;

17-HYDROXYSTEROID DEHYDROGENASES; 17-KETOSTEROIDS; ACNE VULGARIS; ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; NEOPLASMS; OSTEOPOROSIS; PATENTS AS TOPIC;

EID: 77955836270     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2010.505604     Document Type: Review

References (179)

1. Hanson JR. Steroid: partial synthesis in medicinal chemistry. Nat Prod Rep 2007;24:1342-1349 (and other review articles of this series published from 1996)
2. Herson PS, Koerner IP, Hurn PD. Sex, sex steroids, and brain injury. Semin Reprod Med 2009;27:229-239
3. Hamilton NM. Therapeutic potential of steroids for CNS disorders. Expert Opin Ther Pat 2001;11:1523-1531
4. Newman DJ, Cragg GM, Snader KM. The influence of natural products upon drug discovery. Nat Prod Rep 2000;17:215-234
5. Maltais R, Tremblay MR, Ciobanu LC, Poirier D. Steroids and combinatorial chemistry. J Comb Chem 2004;6:443-456
6. Milgrom E. Steroid hormones. In: Baulieu EE, Kelly PA, editors, Hormones: from molecules to disease. Hermann, publishers in arts and science, Paris; 1990. p. 385-437
7. Payne AH, Hales DB. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev 2004;25:947-970
8. Luu-The V, Labrie F. The intracrine sex steroid biosynthesis pathways. In: Martini L, editor, Progress in brain research (Chapter 10). Volume 181. Elsevier; 2010. p. 177-192
9. Labrie F. Intracrinology. Mol Cell Endocrinol 1991;78:C113-8
10. Labrie F, Luu-The V, Labrie C, et al. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 2003;24:152-182
11. Sasano H, Suzuki T, Nakata T, Moriya T. New development in intracrinology of breast carcinoma. Breast Cancer 2006;13:129-136
12. Poirier D. New cancer drugs targeting the biosynthesis of estrogens and androgens. Drug Dev Res 2008;69:304-318
13. von Angerer E. The estrogen receptor as a target for rational drug design. In: Landes RG, editor, Molecular Biology Intelligence Unit, Company, Austin, TX; 1995
14. McEwen BS, Alves SE. Estrogen actions in the central nervous system. Endocr Rev 1999;20:279-307
15. Singh SM, Gauthier S, Labrie F. Androgen, receptor antagonists (antiandrogens): structure-activity relationships. Curr Med Chem 2000;7:211-247
16. Bagatell CJ, Bremner WJ. Androgens in health and disease. Humana Press: Totowa, NJ; 2003
17. Peeters BWMM, Tonnaer JADM, Groen MB, et al. Glucocorticoid receptor antagonists: new tools to investigate disorders characterized by cortisol hypersecretion. Stress 2004;7:233-241
18. Pippal JB, Fuller PJ. Structure-function relationships in the mineralocorticoid receptor. J Mol Endocrinol 2008;41:405-413
19. Jordan VC. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. J Med Chem 2003;46:1081-1111
20. Bhasin S, Jasuja R. Selective androgen receptor modulators as function promoting therapies. Curr Opin Clin Nutr Metab Care 2009;12:232-240
21. Ryan KJ, Engel LL. Interconversion of estrone and estradiol by human tissue slices. Endocrinology 1953;52:287-291
22. Talalay P, Marcus PI. Enzymatic formation of 3 alpha-hydroxysteroids. Nature 1954;173:1189-1190
23. Talalay P, Marcus PI. Specificity, kinetic, and inhibition of alpha-and beta-hydroxysteroid dehydrogenases. J Biol Chem 1956;218:675-691
24. Marcus PI, Talalay P. On the molecular specificity of steroid-enzyme combinations. The kinetics of hydroxy-steroid dehydrogenase. Proc R Soc Lond B 1955;144:116-132
25. Langer LJ, Engel LL. Human placental estradiol-17beta dehydrogenase. J Biol Chem 1958;233:583-588
26. Engel LL, Groman EV. Human placental 17beta-estradiol dehydrogenase: characterization and structural studies. Recent Prog Horm Res 1974;30:139-169
27. Mazumdar M, Zhou M, Zhu DW, et al. Crystallogenesis of steroid-converting enzymes and their complexes: enzyme-ligand interaction studies and inhibitor design facilitated by complex structures. Crystal Growth Des 2007;7:2206-2212
28. Penning TM, Ricigliano JW. Mechanism based inhibition of hydroxysteroid dehydrogenases. J Enz Inh 1991;5:165-198
29. Luu-The V, Belanger A, Labrie F. Androgen biosynthetic pathways in the human prostate. Best Pract Res Clin Endocrinol Metab 2008;22:207-221
30. Moeller G, Adamski J. Integrated view on 17beta-hydroxysteroid dehydrogenases. Mol Cell Endocrinol 2009;301:7-19
31. Review on 17beta-HSDs (role and function).
32. Nagasaki S, Miki Y, Akahira JI, et al. 17beta-Hydroxysteroid dehydrogenases in human breast Cancer. Ann NY Acad Sci 2009;1155:25-32
33. Lukacik P, Kavanagh KL, Oppermann U. Structure and function of human 17beta-hydroxysteroid dehydrogenases. Mol Cell Endocrinol 2006;248:61-71
34. Labrie F, Luu-The V, Lin SX, et al. The key role of 17 beta-hydroxysteroid dehydrogenases in sex steroid biology. Steroids 1997;62:148-158
35. Pelletier G, Luu-The V, Li S, Labrie F. Localization of type 5 17beta-hydroxysteroid dehydrogenase mRNA in mouse tissues as studied by in situ hybridization. Cell Tissue Res 2005;320:393-398 (Pubitemid 40884140)
36. Pelletier G, Luu-The V, Li S, Labrie F. Localization of type 7 17beta-hydroxysteroid dehydrogenase in mouse tissues. In situ hybridization studies. J Steroid Biochem Mol Biol 2005;93:49-57 (Pubitemid 40312733)
37. Pelletier G, Luu-The V, Li S, Labrie F. Localization of type 8 17beta-hydroxysteroid dehydrogenase mRNA in mouse tissues as studied by in situ hybridization. J Histochem Cytochem 2005;53:1257-1271 (Pubitemid 41331124)
38. Sakurai N, Miki Y, Suzuki T, et al. Systemic distribution and tissue localizations of human 17beta-hydroxysteroid dehydrogenase type 12. J Steroid Biochem Mol Biol 2006;99:174-181
39. Luu-The V, Zhang Y, Poirier D, Labrie F. Characteristics of human types 1, 2 and 3 17 beta-hydroxysteroid dehydrogenase activities: oxidation/ reduction and inhibition. J Steroid Biochem Mol Biol 1995;55:581-587
40. Miettinen MM, Mustonen MV, Poutanen MH, et al. Human 17 beta-hydroxysteroid dehydrogenase type 1 and type 2 isoenzymes have opposite activities in cultured cells and characteristic cell-and tissue-specific expression. Biochem J 1996;314:839-845
41. Laplante Y, Rancourt C, Poirier D. Relative involvement of three 17beta-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors. Mol Cell Endocrinol 2009;301:146-153
42. Song D, Liu G, Luu-The V, et al. Expression of aromatase and 17beta-hydroxysteroid dehydrogenase types 1, 7 and 12 in breast cancer. An immunocytochemical study. J Steroid Biochem Mol Biol 2006;101:136-144
43. Adamski J, de Launoit Y. Introduction to the workshop on the molecular and cell biology of hydroxysteroid dehydrogenases. J Steroid Biochem Mol Biol 1995;55:445-446 (and publications in this special issue)
44. Adamski J, Jakob FJ. A guide to 17beta-hydroxysteroid dehydrogenases. Mol Cell Endocrinol 2001;171:1-4 (and publications in this special issue)
45. Adamski J. (Guest editor) The international workshop on 11beta and 17beta-hydroxysteroid dehydrogenases (special issue). Mol Cell Endocrinol 2006;248:1-250
46. Adamski J. (Guest editor) Pre-receptor steroid metabolism as target for pharmacological treatment (special issue). Mol Cell Endocrinol 2009;301:1-282
47. Day JM, Foster PA, Tutill HJ, et al. 17beta-hydroxysteroid dehydrogenase type1, and not type 12, is a target for endocrine therapy of hormone-dependent breast cancer. Int J Cancer 2008;122:1931-1940
48. Penning TM. Molecular endocrinology of hydroxysteroid dehydrogenases. Endocr Rev 1997;18:281-305
49. Labrie F, Luu-The V, Lin SX, et al. Intracrinology: role of the family of 17beta-hydroxysteroid dehydrogenases in human physiology and disease. J Mol Endocrinol 2000;25:1-16
50. Luu-The V. Analysis and characteristics of multiple types of human 17beta-hydroxysteroid dehydrogenase. J Steroid Biochem Mol Biol 2001;76:143-151
51. Moghrabi N, Andersson S. 17beta-Hydroxysteroid dehydrogenases: physiological roles in health and disease. TEM 1998;9:265-270
52. Meier M, Moller G, Adamski J. Perspectives in understanding the role of human 17beta-hydroxysteroid dehydrogenases in health and disease. Ann NY Acad Sci 2009;1155:15-24
53. Peltoketo H, Luu-The V, Simard J, Adamski J. 17beta-Hydroxysteroid dehydrogenase (HSD)/17-ketosteroid reductase (KSR) family; nomenclature and main characteristics of the 17HSD/KSD enzymes. J Mol Endocrinol 1999;23:1-11
54. Vihko P, Herrala A, Harkonen P, et al. Control of cell proliferation by steroids: the role of 17beta-HSDs. Mol Cell Endocrinol 2006;248:141-148
55. Pasqualini JR. The selective estrogen enzyme modulators in breast cancer: a review. Biochim Biophys Acta 2004;1654:123-143
56. Day J, Tutill H, Purohit A, Reed M. Design and validation of specific inhibitors of 17{beta}-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis. Endocr Relat Cancer 2008;15:665-692
57. Chen WC, Thiboutot D, Zouboulis CC. Cutaneous androgen metabolism: basic research and clinical perspectives. J Invest Dermatol 2002;119:992-1007
58. Penning TM. 17beta-hydroxysteroid dehydrogenase: inhibitors and inhibitor design. Endocr Relat Cancer 1996;3:41-56
59. Tremblay MR, Poirier D. Overview of a rational approach to design type I 17beta-hydroxysteroid dehydrogenase inhibitors without estrogenic activity: chemical synthesis and biological evaluation. J Steroid Biochem Mol Biol 1998;66:179-191
60. Poirier D, Bydal P, Tremblay MR, et al. Inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Mol Cell Endocrinol 2001;171:119-128
61. Smith HJ, Nicholls PJ, Simons C, Le Lain R. Inhibitors of steroidogenesis as agents for the treatment of hormone-dependent cancers. Expert Opin Ther Pat 2001;11:789-824
62. Poirier D. Inhibitors of 17beta-hydroxysteroid dehydrogenases. Curr Med Chem 2003;10:453-477
63. Poirier D. Recent advances in development of inhibitors of 17beta-hydroxysteroid dehydrogenases. Anticancer Agents Med Chem 2009;9:642-660
64. Mohler ML, Narayanan R, He Y, et al. Hydroxysteroid dehydrogenase (17beta-HSD3, 17beta-HSD5 and 3alpha-HSD3) inhibitors: extragonadal regulation of intracellular sex steroid hormone levels. Recent Pat Endocr Metab Immune Drug Discov 2007;1:103-108
65. Brozic P, Lanisnik Risner T, Gobec S. Inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. Curr Med Chem 2008;15:137-150
66. Fournier D, Poirier D, Mazumdar M, Lin SX. Design and synthesis of bisubstrate inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: overview and perspectives. Eur J Med Chem 2008;43:2298-2306
67. Washington University. Open D ring hormone analogs. WO8706462; 1987
68. Auchus RJ, Covey DF. Mechanism based inactivation of 17/3,20alpha- hydroxysteroid dehydrogenase by an acetylenic secoestradiol. Biochemistry 1986;25:7295-7300
69. Auchus RJ, Covey DF, Bork V, Schaefer JJ. Solid-state NMR observation of cysteine and lysine Michael adducts of inactivated estradiol dehydrogenase. Biol Chem 1988;263:11640-11645
70. Auchus RJ, Palmer JO, Carrell HL, Covey DF. Preparation of 14,15-secoestra-1,3,5(10)-trien-15-ynes, inhibitors of estradiol dehydrogenase. Steroids 1989;53:77-96
71. Lawate SS, Covey DF. Trifluoromethylacetylenic alcohols as affinity labels: inactivation of estradiol dehydrogenase by a trifluoromethylacetylenic secoestradiol. J Med Chem 1990;33:2319-2321
72. Tobia B, Covey DF, Strickler RC. Inactivation of human placental 17beta-estradiol dehydrogenase and 20alpha-hydroxysteroid dehydrogenase with active site-directed 17beta-propynyl-substituted progestin analogs. J Biol Chem 1982;257:2783-2786
73. Thomas JL, La Rochelle MC, Covey DF, Strickler RC. Inactivation of human placental 17beta,20alpha-hydroxysteroid dehydrogenase by 16-methylene estrone and affinity alkylator enzymatically generated from 16-methylene estradiol-17beta. J Biol Chem 1983;258:11500-11504
74. McDonald ZA, Slikker W Jr, Fu PP, et al. Enhancement of estradiol potency by the 17beta-hydroxysteroid dehydrogenase inhibitor, 16-methylene E2 in vivo. J Pharm Exp Ther 1988;244:428-431
75. Endorecherche, Inc. Androgen derivatives for use in the inhibition of sex steroid activity. WO9100732; 1991
76. Endorecherche, Inc. Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia. WO9100731; 1991
77. Endorecherche, Inc. Method of treatment of androgen-related diseases. WO9100733; 1991
78. Labrie C, Martel C, Dufour JM, et al. Novel compounds inhibit estrogen formation and action. Cancer Res 1992;52:610-615
79. Endorecherche, Inc. Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use. WO9946279; 1999
80. Endorecherche, Inc. Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use. US20040082556; 2004
81. Endorecherche, Inc. Inhibitors of type 5 and type 3 17beta-hydroxysteroid dehydrogenase and methods for their use. US6541463; 2003
82. Bydal P, Auger S, Poirier D. Inhibition of type 2 17beta-hydroxysteroid dehydrogenase by estradiol derivatives bearing a lactone on the D-ring: structure-activity relationship. Steroids 2004;69:325-335
83. Bydal P, Luu-The V, Labrie F, Poirier D. Steroidal lactones as inhibitors of 17beta-hydroxysteroid dehydrogenase type 5: chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities. Eur J Med Chem 2009;44:632-44.
84. Snow Brand Milk Products Co., Ltd. Novel benzofuranone derivatives and process for producing the same. WO9830556; 1998
85. Snow Brand Milk Products Co., Ltd. Novel tetralone or benzopyranone derivatives and process for producing the same. WO9832724; 1998
86. Snow Brand Milk Products Co., Ltd. Remedies for hormone-dependent diseases. WO9912540; 1999
87. Snow Brand Milk Products Co., Ltd. New benzofuranone derivative and production thereof. JP2000038382; 2000
88. University College Cardiff Consultants Ltd. Benzyl tetralins, formulations and uses thereof. WO0142181; 2001
89. Bayer Corp. 17-Beta-hydroxysteroid dehydrogenase-II inhibitors. WO0226706; 2002
90. Cook JH, Baryza J, Brennan C, et al. 4,5-Disubstituted cis-pyrrolidinones as inhibitors of 17beta-hydroxysteroid dehydrogenase II. Part 1: synthetic approach. Tetrahedron Lett 2005;46:1525-1527
91. Gunn D, Akuche C, Baryza J, et al. 4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 2. SAR. Bioorg Med Chem Lett 2005;15:3053-3057
92. Wood J, Bagi CM, Akuche C, et al. 4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 3. Identification of lead candidate. Bioorg Med Chem Lett 2006;16:4965-4968
93. Schering Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases. WO03022835; 2003
94. Schering Corp. Piperidine and piperazineacetamines as 17beta hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases. WO03033487; 2003
95. Schering Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases. US20030232837; 2003
96. Schering Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases. US20040132736; 2004
97. Schering Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases. US6903102; 2005
98. Schering Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases. US696918; 2005
99. Schering Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases. US20060014755; 2006
100. Schering Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases. US20060069103; 2006
101. Schering Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases. US7138396; 2006
102. Schering Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases. WO2004046111; 2004
103. Schering Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases. US20040127503; 2004
104. Schering Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases. WO2004060488; 2004
105. Schering Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases. US20040138226; 2004
106. Schering Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases. US20060142338; 2006
107. Schering Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases. US20060148816; 2006
108. Schering Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases. US20080004248; 2008
109. Schering Corp. 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases. US7432268; 2008
110. Sterix Ltd. Compound. WO2004085457; 2004
111. Sterix Ltd. Compound. US20060074060; 2006
112. Lawrence HR, Vicker N, Allan GM, et al. Novel and potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors. J Med Chem 2005;48:2759-2762
113. Allan GM, Lawrence HR, Cornet J, et al. Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem 2006;49:1325-1345
114. Fischer DS, Allan GM, Bubert C, et al. E-Ring modified steroids as novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J Med Chem 2005;48:5749-5770
115. Allan GM, Bubert C, Vicker N, et al. Novel, potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. Mol Cell Endocrinol 2006;248:204-207
116. Vicker N, Lawrence HR, Allan GM, et al. Focused libraries of 16-substituted estrone derivatives and modified E-ring steroids: inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. ChemMedChem 2006;1:464-481
117. Purohit A, Tutill HJ, Day JM, et al. The regulation and inhibition of 17beta-hydroxysteroid dehydrogenase in breast cancer. Mol Cell Endocrinol 2006;248:199-203
118. Sterix Ltd. Compound. WO2007096647; 2007
119. Sterix Ltd. Compound. US20090186900; 2009
120. Allan GM, Vicker N, Lawrence HR, et al. Novel inhibitors of 17beta-hydroxysteroid dehydrogenase type 1: templates for design. Bioorg Med Chem Lett 2008;16:4438-4456
121. Sterix Ltd. 17beta-hydroxysteroid dehydrogenase type 3 (17beta-HSD3) inhibitors. WO2007003934; 2007
122. Sterix Ltd. Compound. US20090023710; 2009
123. Sterix Ltd. Compound. WO2009066072; 2009
124. Vicker N, Sharland CM, Heaton WB, et al. The design of novel 17b-hydroxysteroid dehydrogenase type 3 inhibitors. Mol Cell Endocrinol 2009;301:259-265
125. Day JM, Tutill HJ, Foster PA, et al. Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17beta-hydroxysteroid dehydrogenase type 3. Mol Cell Endocrinol 2009;301:251-258
126. Vihko P, Isomaa V. Method for prognosticating the progress of breast cancer and compounds useful for prevention or treatment thereof. WO2004080271; 2004
127. Vihko P, Isomaa V. Method for prognosticating the progress of breast cancer and compounds useful for prevention or treatment thereof. US20060057628; 2006
128. Solvay Pharmaceuticals B.V. Thiophenepyrimidinones as 17-beta-hydroxysteroid dehydrogenase inhibitors. WO2004110459; 2004
129. Solvay Pharmaceuticals B.V. Therapeutically active thiophenepyrimidinone compounds and their use. US20050032778; 2005
130. Solvay Pharmaceuticals B.V. Therapeutically active thiophenepyrimidinone compounds and their use. US20080103131; 2008
131. Solvay Pharmaceuticals B.V. Novel compounds and their use in therapy. US20050038053; 2005
132. Solvay Pharmaceuticals B.V. Novel compounds and their use in therapy. WO2005032527; 2005
133. Solvay Pharmaceuticals B.V. Compounds and their use in therapy. US7465739; 2008
134. Solvay Pharmaceuticals B.V. Novel compounds and their use in therapy. US20050176742; 2005
135. Solvay Pharmaceuticals B.V. Compounds and their use in therapy. US7524853; 2009
136. Messinger J, Hirvela L, Husen B, et al. New inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. Mol Cell Endocrinol 2006;248:192-198
137. Solvay Pharmaceuticals B.V. Novel 17beta-hydroxysteroid dehydrogenase type 1 inhibitors. WO2005047303; 2005
138. Solvay Pharmaceuticals B.V. Novel 17beta-hydroxysteroid dehydrogenase type 1 inhibitors. US20050192263; 2005
139. Husen B, Huhtinen K, Saloniemi T, et al. Human hydroxysteroid (17-beta) dehydrogenase 1 expression enhances estrogen sensitivity of MCF-7 breast cancer cell xenografts. Endocrinology 2006;147:5333-5339
140. Husen B, Huhtinen K, Poutanen M, et al. Evaluation of inhibitors for 17beta-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme. Mol Cell Endocrinol 2006;248:109-113
141. Solvay Pharmaceuticals B.V. 17beta-HSD1 and STS inhibitors. WO2006125800; 2006
142. Solvay Pharmaceuticals B.V. 17beta-HSD1 and STS inhibitors. US20060281710; 2006
143. Deluca D, Moller G, Rosinus A, et al. Inhibitory effects of fluorine-substituted estrogens on the activity of 17beta-hydroxysteroid dehydrogenases. Mol Cell Endocrinol 2006;248:218-224
144. Solvay Pharmaceuticals B.V. Therapeutically active triazoles and their use. WO2008034796; 2008
145. Solvay Pharmaceuticals B.V. Therapeutically active triazolesand their use. US20080146531; 2008
146. Solvay Pharmaceuticals B.V. Substituted estratrien derivatives as 17beta HSD inhibitors. WO2008065100; 2008
147. Solvay Pharmaceuticals B.V. Substituted estratrien derivatives as 17beta HSD inhibitors. US20080255075; 2008
148. Vander Jagt DL, Royer RE, Deck LM. 11-Beta-hydroxysteroid dehydrogenase type 1 inhibitors as anti-obesity/ anti-diabetes compounds and 17-beta-hydroxysteroid dehydrogenase type 1 inhibitors as useful agents for the treatment of cancers, especially breast cancer. US20050228038; 2005
149. Brown WM, Metzger LE, Barlow JP, et al. 17beta-Hydroxysteroid dehydrogenase type 1: computational design of active site inhibitors targeted to the Rossmann fold. Chem Biol Interact 2003;143-144:481-491
150. Bristol-Myers Squibb Co. Methods for identifying or screening for agents that modulate 17beta-HSD3. US20050191707; 2005
151. Spires TE, Fink BE, Kick EK, et al. Identification of novel functional inhibitors of 17beta-hydroxysteroid dehydrogenase type III (17beta-HSD3). Prostate 2005;65:159-170
152. Bristol-Myers Squibb Co. Anthranilic acid derivatives as inhibitors of 17beta-hydroxysteroid dehydrogenase3. US20060135619; 2006
153. Bristol-Myers Squibb Co. Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase3. WO2005084296; 2005
154. Bristol-Myers Squibb Co. Fused heterotricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase3. WO2005084295; 2005
155. Bristol-Myers Squibb Co. Fused heterotricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase3. US20050192310; 2005
156. Bristol-Myers Squibb Co. Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase3. US7417040; 2008
157. Schering Aktiengesellschaft. Novel 2-substituted D-homo estra-1,3,5 (10)-trienes as inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. WO2006003012; 2006
158. Schering Aktiengesellschaft. Novel 2-substituted estra-1,3,5(10)-trien- 17-ones used in the form of inhibitors of 17beta-hydroxysteroid dehydrogenase of type 1. WO2006003013; 2006
159. Schering Aktiengesellschaft. New 2-substituted estra-1,3,5(10)-trien-17- ones as inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. US20060009434; 2006
160. Astellas Pharma, Inc. 17beta-HSD type 5 inhibitor. WO2007100066; 2007
161. Astellas Pharma, Inc. Benzimidazole derivative. WO2009014150; 2009
162. Sumitomo Chemical Co. Ltd. Coumarin compound and use thereof. WO2009031706; 2009
163. Sumitomo Chemical Co. Ltd. Coumarin compound and use thereof. WO2009031708; 2009
164. Sumitomo Chemical Co. Ltd. Coumarin compound and use thereof. WO2009031709; 2009
165. Harada K, Kubo H, Tomigahara Y, et al. Coumarins as novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for potential treatment of prostate cancer. Bioorg Med Chem Lett 2010;20:272-275
166. Universitat des Saarlandes. 17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-dependent diseases. WO2008116920; 2008
167. Universitat des Saarlandes. 17Beta-hydroxysteroid-dehydrogenase-typ1- inhibitoren zur behandlung hormonabhangiger erkrankungen. DE102007015169; 2006
168. Universitat des Saarlandes. 17Beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of hormone-dependent diseases. WO2009027346; 2009
169. Universitat des Saarlandes. 17Beta-hydroxysteroid dehydrogenase type 1 inhibitoren zur behandlung hormonabhangiger erkrankungen. DE102007040243; 2009
170. Frotscher M, Ziegler E, Marchais-Oberwinkler S, et al. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases. J Med Chem 2008;51:2158-2169 (Pubitemid 351503271)
171. Marchais-Oberwinkler S, Kruchten P, Frotscher M, et al. Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics. J Med Chem 2008;51:4685-4698
172. Development of a new family of non-steroidal inhibitors of 17beta-HSD1.
173. Marchais-Oberwinkler S, Frotscher M, Ziegler E, et al. Structure-activity study in the class of 6-(3'-hydroxyphenyl) naphthalenes leading to an optimization of a pharmacophore model for 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors. Mol Cell Endocrinol 2009;301:205-211
174. Bey E, Marchais-Oberwinkler S, Kruchten P, et al. Design, synthesis, and biological evaluation of bis (hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases. Bioorg Med Chem 2008;16:6423-6435 (Pubitemid 351783414)
175. Bey E, Marchais-Oberwinkler S, Werth R, et al. Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1). J Med Chem 2008;51:6725-6739
176. Potent non-steroidal inhibitors of 17beta-HSD1 (SAR and in vitro assays).
177. Bey E, Marchais-Oberwinkler S, Negri M, et al. New insights into the SAR and binding modes of bis (hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity. J Med Chem 2009;52:6724-6743
178. Kruchten E, Werth R, Bey E, et al. Selective inhibition of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) reduces estrogen responsive cell growth of T47-D breast cancer cells. J Steroid Biochem Mol Biol 2009;114:200-206
179. Al-Soud YA, Bey E, Oster A, et al. The role of the heterocycle in bis (hydroxyphenyl)triazoles for inhibition of 17beta-hydroxysteroid dehydrogenase (17beta-HSD) type 1 and type 2. Mol Cell Endocrinol 2009;301:212-215